Richard Furman, MD, Discusses Richter's Transformation and Emerging Therapies in CLL

Image removed.


At the 2018 Lymphoma & Myeloma Congress, Richard R. Furman, MD, Director CLL Research Center, Weill Cornell Medicine, New York, New York, spoke with Oncology Learning Network about the CAPTIVATE clinical trial, which examined the first-line treatment of chronic lymphocytic leukemia (CLL) with venetoclax and ibrutinib.

Other topics he discusses in this 3-part video series include CLL progression with BTK inhibitor therapy, and Richter's transformation.

Check out the 3-part series with Dr Furman below!


CAPTIVATE Trial: Venetoclax and Ibrutinib as First-Line Therapy for CLL

Dr Furman discusses the CAPTIVATE trial of ibrutinib and venetoclax as a first line treatment for CLL patients.

Watch Here


CLL Progression on BTK Inhibitor Therapy

Dr Furman discusses CLL progression after BTK inhibitor therapy along with Richter's transformation.

Watch Here


Emerging Treatment Options for Richter's Transformation

Dr Furman discusses Richter's transformation and emerging treatment options currently under investigation to try and improve outcomes for these patients.

Watch Here


Stay in the know.
OncNet Newsletter